Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930375 | 0.84 | CHRNB2 (0.44) | BTKEGFRMAP3K12ATRTLR8 | |
| SCHEMBL25707199 | 0.84 | CHRNB2 (0.44) | BTKEGFRMAP3K12ATRTLR8 | |
| SCHEMBL17651735 | 0.82 | CHRNB2 (0.43) | BTKEGFRMAP3K12ATR | |
| SCHEMBL19897368 | 0.82 | CHRNB2 (0.43) | BTKEGFRMAP3K12ATR | |
| SCHEMBL16437227 | 0.81 | DHFR (0.37) | — | |
| SCHEMBL21706981 | 0.81 | SLC18A3 (0.39) | BTKEGFRMAP3K12ATRTLR8 | |
| SCHEMBL21706977 | 0.81 | SLC18A3 (0.39) | BTKEGFRMAP3K12ATRTLR8 | |
| SCHEMBL19441974 | 0.81 | BTK (0.38) | BTKEGFR | |
| SCHEMBL14925508 | 0.81 | TLR8 (0.40) | BTKEGFRMAP3K12ATRTLR8 | |
| SCHEMBL17662808 | 0.80 | MAPT (0.52) | BTKEGFRATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174254-B2 | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-11-16 | — | — | US | disclosed |
| US-11155546-B2 | 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-10-26 | — | — | US | disclosed |
| EP-3689871-B1 | 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-20200223846-A1 | 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROLO[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVES AND USES THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-07-16 | — | — | US | disclosed |
| US-20200048248-A1 | ANILINE-SUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048248-A1 | ANILINE-SUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE THEREOF | DPYD, ACR, QDPR | BTK 1484/4885EGFR 4038/4885MAP3K12 2890/4885 |
| US-20200223846-A1 | 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROLO[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVES AND USES THEREOF | CYP2D6, DPYD, TPMT | BTK 1081/4885EGFR 4069/4885MAP3K12 2202/4885 |
| US-11155546-B2 | 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof | CYP2D6, DPYD, TPMT | BTK 1081/4885EGFR 4069/4885MAP3K12 2202/4885 |
| US-11174254-B2 | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof | DPYD, ACR, QDPR | BTK 1484/4885EGFR 4038/4885MAP3K12 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.